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Adoptive immunotherapy with antigen-specific T lym-
phocytes is a powerful strategy for cancer treatment.
However, most tumor antigens are non-reactive “self”
proteins, which presents an immunotherapy design chal-
lenge. Studies have shown that tumor-specific T cell
receptors (TCRs) can be transduced into normal periph-
eral blood lymphocytes, which persist after transfer in
about 30% of patients and effectively destroy tumor cells.
Still, recent clinical trial with affinity-enhanced TCRs has
resulted in severe effects due to cross reactivity to an unre-
lated peptide. Thus, the challenge for targeted T cell ther-
apy remains to increase T cell potency in order to improve
clinical responses and ensure on-target specificity by
avoiding unwanted cross reactivity. We used structure-
based design to predict point mutations of a TCR (DMF5)
that enhance its binding affinity for an agonist tumor
differentiation antigen-major histocompatibility complex
(pMHC), Mart-1(27L)-HLA-A2, which elicits full T cell
activation to trigger immune responses. Structural based
approaches have been used to increase TCR affinity,
however their potential cross-reactivity has not been
reported. Here, we analyzed the effects of selected TCR
point mutations alone and in combination on T cell
activation potency. Further, we analyzed their specificity
and cross-reactivity with related antigens presented by
different melanoma cell lines and donor-derived antigen
presenting cells. Our structure-based approach allowed us
to rationally design sequence substitutions that improve
binding in contact areas between the TCR and pMHC
without increasing cross-reactivity with a wide variety of
self-antigens. We identified and evaluated point mutations
in critical TCR positions resulting in more potent T cell
activation but maintaining overall specificity. When double
and triple combination mutations were introduced, they
exhibited an additive enhancement that further impro-
ved T cell activation while retaining a high degree of
specificity.
Conclusions
Such affinity-optimized TCRs could potentially be used in
adoptive immunotherapy to treat melanoma while mini-
mizing adverse autoimmunity effects.
Authors’ details
1NYU School of Medicine, New York, NY, United States. 2Xiangxue
Pharmaceutical Co., Ltd, GuangZhou, Peoples Republic of China. 3NYU, New
York, NY, United States. 4Perelman School of Medicine University of
Pennsylvania, Philadelphia, PA, United States. 5US National Institutes of
Health (NIH), Bethesda, MD, United States.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P28
Cite this article as: Malecek et al.: Specific increase in T cell potency via
structure-based design of a T cell receptor for adoptive immunotherapy.
Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):P28.
1NYU School of Medicine, New York, NY, United States
Full list of author information is available at the end of the article
Malecek et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P28
http://www.immunotherapyofcancer.org/content/2/S3/P28
© 2014 Malecek et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
